Physician profile
David E Larue
NPI 1932248630
$868.94
in general payments reported to CMS, 2019-2025
14 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20.24 · 2020: $31.15 · 2021: $17.15 · 2022: $28.11 · 2024: $317 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $772.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $131.95 | 2025 | |
| Gilead Sciences, INC. | $126.37 | 2025 | |
| Genzyme Corporation | $121.84 | 2024 | |
| Novo Nordisk INC | $120.25 | 2024 | Wegovy |
| Phadia US INC. | $110.18 | 2025 | Immunocap |
| Exact Sciences Corporation | $68.74 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $54.73 | 2019-2024 | Aptima |
| Glaxosmithkline, LLC. | $28.11 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.11 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.70 | 2024 | Xifaxan |
| Lilly USA, LLC | $18.62 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $17.66 | 2025 | Farxiga |
| Abbvie INC. | $17.15 | 2021 | |
| Adlon Therapeutics L.P. | $12.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Larue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.